Mardanpour Keykhosro, Rahbar Mahtab, Mardanpour Sourena, Mardanpour Nyousha, Rezaei Mansour
Kermanshah Medical Science University, Kermanshah, Iran, Islamic Republic of.
Iran Medical Science University, Tehran, Iran, Islamic Republic of.
Tumour Biol. 2020 Dec;42(12):1010428320975976. doi: 10.1177/1010428320975976.
The abundance and location of CD8+ tumor-infiltrating lymphocytes demonstrate important facets of the anticancer immune response. CD8-expressing lymphocytes have been used in immunotherapy for multiple cancers. This study aims to determine the association between the abundance and localization of CD8+ tumor-infiltrating lymphocytes and clinical outcomes of Wilms' tumor. This retrospective study employed 42 pediatric patients diagnosed with Wilms' tumor. CD8+ tumor-infiltrating lymphocyte counts were calculated based on the mean percentage of stroma occupied by CD8+ lymphocytes at the center and the invasive border of the tumor using immunohistochemistry. CD8+ tumor-infiltrating lymphocyte counts were significantly higher in the center and the invasive border of the early-stage tumor samples. CD8+ tumor-infiltrating lymphocytes in the invasive border and tumor center positively correlated with tumor invasion, regional lymph node invasion, histological type, metastasis, and stage of the tumor. A high CD8+ tumor-infiltrating lymphocyte scores at the invasive margin of the tumor correlated with low tumor recurrence. Low CD8+ tumor-infiltrating lymphocyte scores in the two tumor regions correlated with poor prognosis and shorter disease-free survival. Overall, these findings show that patients with high CD8+ tumor-infiltrating lymphocytes are associated with better clinical outcomes. Therefore, measuring the abundance of CD8+ tumor-infiltrating lymphocytes may be useful in predicting response to cancer immunotherapies.
CD8+肿瘤浸润淋巴细胞的数量和位置体现了抗癌免疫反应的重要方面。表达CD8的淋巴细胞已被用于多种癌症的免疫治疗。本研究旨在确定CD8+肿瘤浸润淋巴细胞的数量和定位与肾母细胞瘤临床结果之间的关联。这项回顾性研究纳入了42例被诊断为肾母细胞瘤的儿科患者。使用免疫组织化学方法，根据肿瘤中心和浸润边缘CD8+淋巴细胞所占基质的平均百分比来计算CD8+肿瘤浸润淋巴细胞计数。早期肿瘤样本的中心和浸润边缘的CD8+肿瘤浸润淋巴细胞计数显著更高。浸润边缘和肿瘤中心的CD8+肿瘤浸润淋巴细胞与肿瘤浸润、区域淋巴结浸润、组织学类型、转移及肿瘤分期呈正相关。肿瘤浸润边缘的高CD8+肿瘤浸润淋巴细胞评分与低肿瘤复发相关。两个肿瘤区域的低CD8+肿瘤浸润淋巴细胞评分与预后不良和无病生存期较短相关。总体而言，这些发现表明，CD8+肿瘤浸润淋巴细胞数量高的患者临床结果较好。因此，测量CD8+肿瘤浸润淋巴细胞的数量可能有助于预测癌症免疫治疗的反应。
